local
Merck buying Twin Cities medtech firm Bio-Techne for $11.3B
Summary by The Minneapolis Editorial Desk · As published by Star Tribune
· June 25, 2026
· 1 min read
Photo: Star Tribune · view original
Story provenance No corrections
Summary created by The Minneapolis Editorial Desk — automated, rule-governed Published by Star Tribune Original story Read at the source Source published Jun 25, 2026 AI assistance Automated summary drawn from the source’s own published text Prepublication human review No — editorial rules, flagged-item review, and published samples
Every story comes with a passport. How we work · Corrections log
Key takeaway Merck is purchasing Bio-Techne, a 50-year-old firm based in the area, for $11.
A major acquisition is underway in the Twin Cities medical technology sector. 3 billion. The sale comes after Bio-Techne faced pressure from activist groups to sell.
Further details about the acquisition and its implications are available from the Star Tribune. For those seeking more information about the deal and its potential impact on the local medtech industry, additional reporting can be found in the Star Tribune's coverage of the acquisition.
Why this matters
Local news anchors readers in their community — the people, places, and decisions that shape day-to-day life. The Minneapolis covers these stories because national outlets often won't.
About this story
As published by Star Tribune . The Minneapolis surfaces reporting from trusted publishers and adds local editorial context so readers can quickly understand what a story means for their community. We attribute every source, link to the original report, and follow a documented editorial standards policy. To understand how stories are selected and reviewed, read our about page .
For the complete original report, visit Star Tribune . Have a tip or correction? Contact our newsroom .
Category: local ·
Published: June 25, 2026 ·
Source: Star Tribune ·
Reading time: 1 min
Frequently asked about this story
What is this story about? A major acquisition is underway in the Twin Cities medical technology sector. Merck is purchasing Bio-Techne, a 50-year-old firm based in the area, for $11.3 billion. The sale comes after Bio-Techne…
When was this published? This article was first published on June 25, 2026 by Star Tribune and curated for The Minneapolis readers.
Who reported this story? This story was reported by Star Tribune. To learn more about how The Minneapolis selects and reviews stories, see our editorial standards .
Where can I find related coverage? See more local coverage from The Minneapolis, or browse our daily briefing and topic hubs .
← Back to all news
More local →
Today’s briefing
Subscribe to newsletter